ANEBULO PHARMACEUTICALS INC (ANEB) Stock News

USA - Nasdaq - NASDAQ:ANEB - US0345691036 - Common Stock

2.36 USD

+0.02 (+0.85%)

Last: 12/1/2025, 8:00:00 PM

2.36 USD

0 (0%)

After Hours: 12/1/2025, 8:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ANEB Latest News, Press Relases and Analysis

All

Press Releases

19 days ago - By: Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates

2 months ago - By: Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates

2 months ago - By: Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity

2 months ago - By: Benzinga - Mentions: NXST SBGI DIS TGNA ...

Deal Dispatch: Need M&A Approval? FCC Chair Explains How To Get It

2 years ago - By: BusinessInsider

News Image

ANEB Stock Earnings: Anebulo Pharmaceuticals Beats EPS for Q3 2024

3 months ago - By: Benzinga - Mentions: GRI IVA COCP ADXN ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

3 months ago - By: Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives

4 months ago - By: Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock

7 months ago - By: Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates

10 months ago - By: Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates

a year ago - By: Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise

a year ago - By: Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates

a year ago - By: Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates

a year ago - By: Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects

a year ago - By: Lifecore Biomedical, Inc. - Mentions: LFCR LGND QLGN

Lifecore Biomedical Announces Cooperation Agreement with 22NW

2 years ago - By: InvestorPlace

ANEB Stock Earnings: Anebulo Pharmaceuticals Beats EPS for Q3 2024

2 years ago - By: Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates

2 years ago - By: Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates

2 years ago - By: Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates

2 years ago - By: Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals Announces New CEO

2 years ago - By: Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors

2 years ago - By: Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates